Skip to content

Telbivudine

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: beta-L-Thymidine, epavudine, L-Thymidine, sebivo

OfmEMA approvedFDA approvedATC J05AF11

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Telbivudine is an ofm drug in the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2006. Its mechanism of action is classified as Nucleoside Reverse Transcriptase Inhibitors. DrugCentral lists 2 molecular targets, including HBcAg and P. Recorded indications include Chronic type B viral hepatitis.

  • Approval status: ofm (first approved 2006 by the FDA).
  • Drug class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor.
  • Mechanism of action: Nucleoside Reverse Transcriptase Inhibitors.
  • Molecular targets: HBcAg and P (2 listed in DrugCentral).
  • Indications: Chronic type B viral hepatitis.
  • ATC code: J05AF11 (Nucleoside and nucleotide reverse transcriptase inhibitors).
  • Molecular formula: C10H14N2O5; molecular weight 242.23 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Chronic type B viral hepatitis

Contraindications (7)

  • Breastfeeding (mother)
  • Disorder of muscle
  • Kidney disease
  • Lactic acidosis
  • Myositis
  • Peripheral nerve disease
  • Steatosis of liver

Mechanism & targets

Mechanism of action (MoA)Nucleoside Reverse Transcriptase Inhibitors
Established pharmacologic classHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Molecular targets (2)

TargetGeneActionActivity
Capsid proteinHBcAgunknownEC50 6.09
Protein PPinhibitorEC50 5.89

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2007-04-24EMA——
2006-10-25FDA—NOVARTIS

ATC classification

ATC codeTherapeutic hierarchy
J05AF11ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Nucleoside and nucleotide reverse transcriptase inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Drug resistance394.3
Blood creatine phosphokinase increased234.9
Pathogen resistance205.8
Viral mutation identified183.9
Hepatitis B DNA increased125.7
Myalgia97.1

Chemical structure

Molecular formulaC10H14N2O5
Molecular weight242.23 g/mol
CAS number3424-98-4
InChIKeyIQFYYKKMVGJFEH-CSMHCCOUSA-N
PubChem CID159269
CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Telbivudine used for?

DrugCentral lists the following indications for Telbivudine: Chronic type B viral hepatitis.

How does Telbivudine work?

Telbivudine is classified as Nucleoside Reverse Transcriptase Inhibitors; its molecular targets in DrugCentral include HBcAg and P (inhibitor).

When was Telbivudine first approved?

Telbivudine was first approved by the FDA in 2006.

What drug class does Telbivudine belong to?

Telbivudine is in the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class.

What is the chemical formula of Telbivudine?

Telbivudine has the molecular formula C10H14N2O5 and a molecular weight of 242.23 g/mol.

Browse: all drugs starting with T · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval2006-10-25
AgencyFDA
Targets2
Indications1
FormulaC10H14N2O5
DrugCentral ID4220
Interactive profile